ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015
Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial.Journal of the National Cancer Institute · 2021Trial
- Trial
- Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy.International journal of radiation oncology, biology, physics · 2017Trial
- How Would You Treat? A Case-Vignette Study of Provider Treatment Preferences in Human Papillomavirus-Mediated Oropharyngeal Cancer.Head & neck · 2026Article
- Multimodal Radiogenomic Imaging in Oropharyngeal Squamous Cell Carcinoma: Implications for Dentomaxillofacial Radiology.Medical sciences (Basel, Switzerland) · 2026Review
- Human Papillomavirus-Positive Oropharyngeal Cancer: Clinical and Radiologic Characteristics.Journal of the Korean Society of Radiology · 2026Review
- Upfront surgery versus definitive radiotherapy: competing risk analyses for cancer-specific and noncancer mortality in oropharyngeal cancer.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- Article
- Article
- Article
- Review
- Article
- Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study.Lancet regional health. Americas · 2022Article
- Prognostic role of pre-treatment serum ALB in Patients with oropharyngeal cancer: A retrospective cohort study.Frontiers in oncology · 2022Article
- Current Therapeutic Strategies in Patients with Oropharyngeal Squamous Cell Carcinoma: Impact of the Tumor HPV Status.Cancers · 2021Review
- Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness.BMC cancer · 2021Article
- Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma.International journal of oral science · 2021Review
- A MicroRNA Expression Signature as Prognostic Marker for Oropharyngeal Squamous Cell Carcinoma.Journal of the National Cancer Institute · 2021Article
- Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2021Review
Corrections and comments
- Erratum issuedErrata.2018
Authors and funding
2 authors.
Funding
Abstract
Human papillomavirus-associated oropharynx cancer (HPVA-OPC) is rapidly increasing in incidence and has unique epidemiologic, molecular, and biologic characteristics. Despite being recognized as having superior prognosis, current evidence does not support less intense therapy compared with HPV-negative OPC. Current combined modality therapies confer a significant risk of morbidity, and patients with HPVA-OPC have a younger median age. These patients, therefore, live longer with the adverse effects of treatment, and this spurs the development of treatment deintensification trials that attempt to decrease treatment-related morbidity without compromising efficacy. Many radiation and chemotherapy de-escalation trials are underway. Minimally invasive surgical techniques are also being evaluated. It is important to identify the ideal patient group for treatment deintensification and to define prognostic risk groups to avoid undertreating the poorer-risk subset in HPVA-OPC, and validated biomarkers are needed to identify patients with the best prognosis. Significant smoking exposure mitigates the favorable prognosis of HPVA-OPC. Currently, less intense treatment is an option only in the setting of clinical trials, and patients with HPVA-OPC should be offered clinical trial options whenever they are available. Finally, recognition of novel therapeutic targets and signaling pathways is critical to the development of new treatment strategies that are desperately needed for patients with poor risk and those with recurrent and metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.